-
LIXT Dashboard
- Financials
- Filings
-
Holdings
-
Transcripts
- ETFs
- Insider
- Institutional
- Shorts
Lixte Biotechnology (LIXT)
Company Profile
Quarter (USD) | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 1 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Proequities | 0.00 | $0.00 |
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
20 Jan 25 | Rene Bernards | Options to Purchase Common Stock Common | Grant | Acquire A | No | No | 2.33 | 4,166 | 9.71 k | 4,166 |
20 Jan 25 | Regina Brown | Options to Purchase Common Stock Common | Grant | Acquire A | No | No | 2.33 | 4,924 | 11.47 k | 4,924 |
20 Jan 25 | Yun Yen | Options to Purchase Common Stock Common | Grant | Acquire A | No | No | 2.33 | 4,545 | 10.59 k | 4,545 |
20 Jan 25 | Stephen J. Forman | Options to Purchase Common Stock Common | Grant | Acquire A | No | No | 2.33 | 3,030 | 7.06 k | 3,030 |
30 Sep 24 | Rene Bernards | Options to Purchase Common Stock Common | Grant | Acquire A | No | No | 1.3 | 5,304 | 6.90 k | 5,304 |